NovoCure Limited NVCR
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +1.70%
- 1 year
- +2.57%
- Open
- 12.81
- Prev close
- 13.11
- Mkt cap
- 1.54B
- Vol
- 1.97M
- Avg vol
- 1.44M
- EPS
- -1.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.53
- High
- 13.26
- Forward P/E
- -16.31
- Beta
- 0.00
- Short ratio
- 9.27
- Inst. own
- 90.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 15.88
- 200-d avg
- 14.82
- 1y target
- 26.86
News
7 hours ago fool.com
NovoCure: 3 Key Takeaways for Long-Term Investors
NovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.
-
2 days ago benzinga.com
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15
Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and lowers the price target from $20 to $15.
-
2 days ago benzinga.com
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.
3 days ago seekingalpha.com
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
NovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO &…
3 days ago marketbeat.com
NovoCure Q3 Earnings Call Highlights
NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped…
3 days ago zacks.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.
3 days ago benzinga.com
NovoCure Q3 2026 Earnings Call Transcript
NovoCure (NASDAQ:NVCR) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
3 days ago benzinga.com
NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M Estimate
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.24) by 62.5 percent. This is a 72.73 percent increase over losses of $(0.33) per…
-
3 days ago benzinga.com
NovoCure Raises FY2026 Sales Guidance from $710.000M-$725.000M to $736.000M-$743.000M vs $725.814M Est
NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $710.000 million-$725.000 million to $736.000 million-$743.000 million vs $725.814 million estimate.
3 days ago businesswire.com
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to…
4 days ago businesswire.com
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of…